Yong Yuan

发表

Effects of ambulatory-care pharmacist consultation on mortality and hospitalization.

J. Hay, J. Mccombs, Yong Yuan, 2003, The American journal of managed care.

Five Laboratory Tests Predict Patient Risk and Treatment Response in Hepatitis C: Veterans Affairs Data from 1999-2010

G. L’italien, J. Mccombs, S. Saab, 2016 .

Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.

Jinlin Song, J. Signorovitch, E. Swallow, 2016, Journal of comparative effectiveness research.

Using the Fib-4 Score to Monitor Morbidity and Mortality Risk in Chronic Hepatitis C Patients

J. Mccombs, S. Saab, T. Matsuda, 2016 .

Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection.

Chien-Jen Chen, G. L’italien, Hwai I. Yang, 2014, Value in health regional issues.

Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model

R. Kim, P. McEwan, Yong Yuan, 2013, Applied Health Economics and Health Policy.

Epidemiology, treatment and health economics of Hepatitis C in Japan (Review)

I. Kamae, P. McEwan, M. Kobayashi, 2014 .

Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies

B. Jones, J. Gordon, P. McEwan, 2017, The European Journal of Health Economics.

Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.

D. Stenehjem, K. Betts, D. Waterhouse, 2021, Lung cancer.

Epidemiology and natural history of hepatitis C virus infection.

Chien-Jen Chen, G. L’italien, Hwai I. Yang, 2014, World journal of gastroenterology.

Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma

G. Dranitsaris, D. Liew, P. McEwan, 2020, ClinicoEconomics and outcomes research : CEOR.

Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma

G. Dranitsaris, D. Liew, P. McEwan, 2019, Journal of medical economics.

G. L’italien, K. Chayama, J. Toyota, 2014, Value in health regional issues.

Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.

E. Wu, C. Behrer, D. Macaulay, 2015, Journal of managed care & specialty pharmacy.

Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.

T. Le, E. Wu, D. Macaulay, 2015, Clinical therapeutics.

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

P. McEwan, T. Ward, Yong Yuan, 2017, Cost Effectiveness and Resource Allocation.

The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK

J. Gordon, P. McEwan, T. Ward, 2015, European journal of gastroenterology & hepatology.

Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States

R. Maclean, Yong Yuan, L. Rosenblatt, 2010, Journal of medical economics.

Economic burden associated with patients diagnosed with hepatitis C.

J. Mccombs, S. Saab, Yong Yuan, 2011, Clinical Therapeutics.

Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States

J. Penrod, N. Varol, Yong Yuan, 2022, Journal of medical economics.

Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States

J. Penrod, J. Maervoet, M. Polyzoi, 2022, Journal of medical economics.

Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.

U. Iloeje, S. Saab, Yong Yuan, 2008, Journal of managed care pharmacy : JMCP.

Reply: Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States

M. Ganz, B. Sill, Yong Yuan, 2017, Journal of medical economics.

The impact of timing and prioritization on the cost‐effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States

G. L’italien, R. Kim, P. McEwan, 2013, Hepatology.

Hepatitis C viral load, genotype, and increased risk of developing end‐stage renal disease: REVEAL‐HCV study

Chien-Jen Chen, G. L’italien, K. Chien, 2017, Hepatology.

A Glycomarker for Short-term Prediction of Hepatocellular Carcinoma: A Longitudinal Study With Serial Measurements

Chien-Jen Chen, G. L’italien, J. Liu, 2018, Clinical and Translational Gastroenterology.

Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections

P. McEwan, D. Sugrue, Yong Yuan, 2015, PloS one.

1137-77 Long-term cost-effectiveness of clopidogrel in patients having percutaneous coronary intervention early after acute coronary syndrome: Results from PCI-CURE

S. Yusuf, S. Mehta, W. Weintraub, 2004 .

Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer.

D. Camidge, J. Jansen, J. Penrod, 2020, Journal of comparative effectiveness research.

Measuring the Value Healthy Individuals Place on Generous Insurance Coverage of Severe Diseases: A Stated Preference Survey of Adults Diagnosed With and Without Lung Cancer.

J. Penrod, J. Romley, K. Bognar, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Estimating the cost‐effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b

I. Kamae, P. McEwan, M. Kobayashi, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

J. Borrill, B. Jones, J. Gordon, 2021, PharmacoEconomics - Open.

Multicountry Burden of Chronic Hepatitis C Viral Infection among Those Aware of Their Diagnosis: A Patient Survey

G. L’italien, J. Mauskopf, M. Dibonaventura, 2014, PloS one.

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

Yong Li, Chenhong Fang, Yong Yuan, 2022, Frontiers in Immunology.

Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease

B. Jones, J. Gordon, P. McEwan, 2016, Clinical Drug Investigation.

Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma

Chien-Jen Chen, G. L’italien, Hwai I. Yang, 2014, International journal of cancer.

Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b.

I. Kamae, S. Berry, K. Broglio, 2014, Value in health regional issues.

Burden of Viral Hepatitis C in Japan: A Propensity Analysis of Patient Outcomes

G. L’italien, P. Langley, M. Dibonaventura, 2011 .

Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B

U. Iloeje, Yong Yuan, G. Cook, 2008, Applied health economics and health policy.

Projecting long-term graft and patient survival after transplantation.

Andrew H Briggs, Adrian R Levy, G. L’italien, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Development of a parametric simulation model for forecasting goal-oriented treatment outcomes.

G. L’italien, Roland S. Chen, Yong Yuan, 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients

Chien-Jen Chen, Hwai I. Yang, Mei-Hsuan Lee, 2017, Scientific Reports.

Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset

D. Stenehjem, K. Betts, D. Waterhouse, 2021, Data in brief.

Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program.

U. Iloeje, G. Yao, Yong Yuan, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C

P. McEwan, T. Ward, Yong Yuan, 2015, PloS one.

The epidemiologic burden of hepatitis C virus infection in Latin America .

A. Levy, G. Castañeda-Hernández, R. Jiménez-Méndez, 2012 .

The epidemiologic burden of hepatitis C virus infection in Latin America .

A. Levy, G. Castañeda-Hernández, R. Jiménez-Méndez, 2011, Annals of hepatology.

The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry.

Sammy Saab, G. L’italien, J. Mccombs, 2014, JAMA internal medicine.

A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan

Chien-Jen Chen, J. Kao, K. Johnston, 2015, Hepatology International.

Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System.

J. Hay, T. Cheetham, L. Nyberg, 2015, Journal of managed care & specialty pharmacy.

Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C.

R. Kim, P. McEwan, R. Townsend, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens.

R. Lewis, E. Daar, B. Spellberg, 2015, Journal of comparative effectiveness research.

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.

M. Provencio, J. Penrod, F. Franke, 2019, European journal of cancer.

Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan

J. Penrod, M. Dibonaventura, K. Higginbottom, 2019, Therapeutics and clinical risk management.

Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer

D. Camidge, J. Penrod, C. Smare, 2021, Journal of medical economics.

Polymorphisms near the IFNL3 Gene Associated with HCV RNA Spontaneous Clearance and Hepatocellular Carcinoma Risk

Chien-Jen Chen, G. L’italien, Hwai I. Yang, 2015, Scientific Reports.

Review of patient-reported outcome measures in chronic hepatitis C

G. L’italien, D. Revicki, L. Kleinman, 2012, Health and Quality of Life Outcomes.

Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome‐wide association study

Chien-Jen Chen, Hwai I. Yang, Sheng-Nan Lu, 2018, Hepatology.

Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation.

S. Yusuf, J. Caro, S. Mehta, 2006, American heart journal.

The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan.

G. L’italien, P. Langley, M. Dibonaventura, 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.

S. Yusuf, J. Caro, W. Weintraub, 2005, Journal of the American College of Cardiology.

The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature

J. Penrod, B. Bennett, Yong Yuan, 2016, Front. Pharmacol..

Humanistic and economic impacts of hepatitis C infection in the United States

G. L’italien, P. Langley, M. Dibonaventura, 2010, Journal of medical economics.

Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: A systematic literature review (SLR)

J. Penrod, Yong Yuan, A. Enstone, 2019, PloS one.

High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease.

Chien-Jen Chen, G. L’italien, K. Chien, 2017, Kidney international.

A clinician’s guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective

M. Thursz, J. Gordon, P. McEwan, 2017, European journal of gastroenterology & hepatology.

Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.

S. Mehta, W. Weintraub, P. Kolm, 2007, The Canadian journal of cardiology.

The burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes

G. L’italien, P. Langley, Yong Yuan, 2012, European journal of gastroenterology & hepatology.

Chronic hepatitis C virus infection and the risk for diabetes: a community‐based prospective study

Chien-Jen Chen, G. L’italien, Hwai I. Yang, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States

M. Ganz, B. Sill, Yong Yuan, 2017, Journal of medical economics.

The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities

G. L’italien, P. Langley, M. Dibonaventura, 2011, Journal of medical economics.

Development and Validation of a Clinical Scoring System for Predicting Risk of HCC in Asymptomatic Individuals Seropositive for Anti-HCV Antibodies

Chien-Jen Chen, G. L’italien, Hwai I. Yang, 2014, PloS one.

Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy.

D. Stenehjem, K. Betts, D. Waterhouse, 2021, Future oncology.

Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance

Chien-Jen Chen, G. L’italien, Hwai I. Yang, 2017, Oncotarget.

First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 ≥ 1%: Patient-Reported Outcomes From CheckMate 227 Part 1.

K. Syrigos, K. O'Byrne, T. Ciuleanu, 2021, Journal of Thoracic Oncology.

The Economic Burden of Small Cell Lung Cancer: A Systematic Review of the Literature

J. Penrod, Yong Yuan, A. Enstone, 2017, PharmacoEconomics - Open.

Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.

Jinlin Song, Caroline Kelley, Jinlin Song, 2016, Clinical therapeutics.

Productivity cost model of the treatment of rheumatoid arthritis with abatacept

R. Marioni, W. Burton, A. Morrison, 2008, Journal of medical economics.

The Impact of Government Income Transfers on Tobacco and Alcohol Use: Evidence from China

Gordon Liu, R. Myerson, Yong Yuan, 2019 .

Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.

U. Iloeje, Yong Yuan, G. Cook, 2008, Applied health economics and health policy.

Evaluation of the Cost-Effectiveness of Entecavir Versus Lamivudine in Hepatitis BeAg-Positive Chronic Hepatitis B Patients

U. Iloeje, S. Saab, Yong Yuan, 2008, Journal of managed care pharmacy : JMCP.

Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer.

J. Jansen, J. Penrod, D. Ayers, 2019, Journal of comparative effectiveness research.

A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer

S. Ramsey, J. Roth, M. Othus, 2020, Journal of medical economics.